Therapeutic cancer vaccine: building the future from lessons of the past
10.1007/s00281-018-0691-z · 2019
The interplay of immunotherapy and chemotherapy: harnessing potential synergies
10.1158/2326-6066.cir-15-0064 · 2015
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
10.1126/scitranslmed.aad8307 · 2016
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival
10.1126/scitranslmed.aaz8235 · 2020
The Human Vaccines Project: A roadmap for cancer vaccine development
10.1126/scitranslmed.aaf0685 · 2016
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
10.1136/jitc-2021-003218 · 2021
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial
10.1001/jamaoncol.2018.4051 · 2019
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
10.1016/j.ccell.2022.08.003 · 2022
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC
10.1016/j.ccell.2022.08.002 · 2022
Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
10.1016/j.immuni.2018.12.021 · 2019
T cell factor 1: A master regulator of the T cell response in disease
10.1126/sciimmunol.abb9726 · 2020
TCF1 in T cell immunity: a broadened frontier
10.1038/s41577-021-00563-6 · 2022
Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory
10.1073/pnas.0914127107 · 2010
Ectopic Tcf1 expression instills a stem-like program in exhausted CD8(+) T cells to enhance viral and tumor immunity
10.1038/s41423-020-0436-5 · 2021
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
10.1038/ncomms12150 · 2016
Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression
10.1016/j.celrep.2023.112599 · 2023
The GSK3beta-beta-catenin-TCF1 pathway improves naive T cell activation in old adults by upregulating miR-181a
10.1038/s41514-021-00056-9 · 2021
4-1BB signaling activates the t cell factor 1 effector/beta-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T Cells
2013
Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor
10.1084/jem.183.2.439 · 1996
LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
10.1038/s41467-021-27179-7 · 2021
BCL6 promotes a stem-like CD8(+) T cell program in cancer via antagonizing BLIMP1
10.1126/sciimmunol.adh1306 · 2023
Novel H-2D(b)-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice
10.1136/jitc-2024-008998 · 2024
Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
10.1159/000526481 · 2022
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance
10.1038/s41590-019-0441-y · 2019
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
10.1158/1078-0432.ccr-21-2834 · 2022
The importance of correctly timing cancer immunotherapy
10.1080/14712598.2017.1256388 · 2017
Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide
10.1158/0008-5472.can-10-4523 · 2011
Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma
10.1016/j.isci.2022.104995 · 2022
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1(-)CD8(+) Tumor-Infiltrating T Cells
10.1016/j.immuni.2018.11.014 · 2019
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade
10.1182/bloodadvances.2022007046 · 2022
Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy
10.1016/j.ccell.2023.08.001 · 2023
The Potential of T Cell Factor 1 in Sustaining CD8(+) T Lymphocyte-Directed Anti-Tumor Immunity
10.3390/cancers13030515 · 2021
beta-Catenin expression is regulated by an IRES-dependent mechanism and stimulated by paclitaxel in human ovarian cancer cells
10.1016/j.bbrc.2015.03.161 · 2015
beta-catenin/TCF-1 pathway in T cell development and differentiation
10.1007/s11481-012-9367-y · 2012
Constitutive activation of Wnt signaling favors generation of memory CD8 T cells
10.4049/jimmunol.0901199 · 2010
Suppression of Tcf1 by Inflammatory Cytokines Facilitates Effector CD8 T Cell Differentiation
10.1016/j.celrep.2018.01.072 · 2018
An engineered IL-2 partial agonist promotes CD8(+) T cell stemness
10.1038/s41586-021-03861-0 · 2021
cGAS-STING-mediated DNA sensing maintains CD8(+) T cell stemness and promotes antitumor T cell therapy
10.1126/scitranslmed.aay9013 · 2020
Low-avidity T cells drive endogenous tumor immunity in mice and humans
10.1038/s41590-024-02044-z · 2025
Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1
10.1136/jitc-2023-007114 · 2023
